Novavax shares fall on RSV, NanoFlu vaccine updates

Novavax officials said they're on pace to submit biologics license application with the U.S. Food and Drug Administration by late 2019 — but investors clearly harbor concerns.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.